Drugs / Trametes versicolor
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00680667 | Apr 2007 → Apr 2011 | breast cancer | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04667247 | Dec 2020 → Mar 2022 | COVID-19 | Gordon Saxe | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trametes versicolor | “This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv),...” NCT04667247 ↗1“Females with Stage I-III infiltrating ductal adenocarcinoma of the breast being treated with Trametes versicolor capsules for 6 weeks after receiving radiation therapy.” NCT00680667 ↗ |
| Route | Oral | “Patients receive oral coriolus versicolor extract twice daily for 6 weeks.” NCT00680667 ↗ |